Historical collection · First published Nov 1, 2024; added to EM Weekly Oct 27, 2026. This retrospective summary may be superseded by later evidence or guidance.
← All articlesACMT Statement on Fentanyl “Exposure” Laws
Summary
ACMT states that incidental proximity or dermal contact with street fentanyl does not cause opioid intoxication and that routine handling requires standard precautions rather than extraordinary decontamination. It recommends nitrile gloves for routine handling, prompt soap-and-water washing after incidental dermal exposure, eye and face protection when splash is possible, and naloxone for objective hypoventilation rather than failure to awaken.
Why it matters
For ED and EMS clinicians, the statement supports basing treatment on an objective opioid toxidrome rather than exposure anxiety and avoiding unnecessary escalation for asymptomatic incidental contact. This is historical guidance: a newer ACMT/AACT occupational-opioid-exposure statement was published online October 16, 2025 (https://link.springer.com/article/10.1007/s13181-025-01101-9); consult that guidance for current operational details.
Study at a glance
- Design
- Consensus statement
- Population
- Emergency responders and other workers with incidental occupational exposure concerns involving illicit fentanyl or fentanyl analogs.
- Sample size
- Not applicable
- Intervention
- ACMT recommendations for risk communication, personal protection, decontamination, naloxone use, and airway management after occupational fentanyl exposure.
- Comparator
- Fear-based or nonspecific management of incidental exposure; not a comparative trial.
- Primary endpoint
- Expert position on prevention and management of occupational fentanyl exposure and the clinical response to suspected opioid intoxication.
Main findings
- Incidental proximity or dermal contact with street fentanyl is not expected to cause opioid intoxication; routine handling with nitrile gloves is considered sufficient protection.
- After incidental dermal exposure, wash with water, preferably soap; use eye and face protection for tasks with splash risk.
- Administer naloxone for objective hypoventilation rather than failure to awaken; provide advanced airway support when clinically indicated.
- The 2025 ACMT/AACT occupational-opioid-exposure statement is newer and should be used for current operational details.
Limitations
This is a professional-society position statement rather than a formal graded guideline, and it addresses incidental occupational exposure rather than deliberate ingestion, injection, needlestick injury, or confirmed opioid poisoning. Consult the newer ACMT/AACT guidance, published online October 16, 2025, for current operational details; its paywalled full text was not reviewed here.
Recommendation strength
ACMT Board-approved position statement based on literature review and expert judgment; no formal GRADE strength was reported.
Read the primary source
Full text: Official PDF available.
Original source Official source PDFSource: https://www.acmt.net/news/acmt-position-statement-on-fentanyl-exposure-laws/
Material reviewed: full text. Latest correction: Oct 27, 2026.
Source retrieved Oct 27, 2026. Historical backfill. The official ACMT page and legal PDF dated 2024-11-01 were reviewed. The official ACMT statement directory identifies this as its November 2024 position statement. Springer publisher metadata for the newer ACMT/AACT occupational-opioid-exposure statement (https://link.springer.com/article/10.1007/s13181-025-01101-9) explicitly give Published and Version of record as 2025-10-16; January 2026 is the print issue. Only publisher metadata and the paywalled preview of the newer statement were reviewed, not its full text. This older record is historical rather than a claim about current operational guidance.
Corrections & review history
Oct 27, 2026 — Corrected the cited newer ACMT/AACT occupational-opioid-exposure statement reference from November 2025 / 2025-11-11 to its publisher-verified first-online/version-of-record date of 2025-10-16 (https://link.springer.com/article/10.1007/s13181-025-01101-9); January 2026 is the print issue. Removed the unverified claim about changed naloxone ceiling details. The original 2024 statement findings and first-online date are unchanged; the newer statement full text was not reviewed.